

Date: __/__/____

RE: Patient Name: _____

Policy Number / Health Card Number _____

Re: Request for funding for SpeediCath® catheter, continence supplies

Insurer:

Dear Insurer,

<Name> _____ has been assessed as requiring intermittent catheterisation for management of neurogenic bladder. Under <Name> _____ current bladder program of <Describe current routine> _____, it has been determined that he/she has experienced the following:

- Recurrent UTI (urinary tract infections) symptoms may include:
 - Autonomic Dysreflexia
 - Fever
 - Soreness in back or sides
 - Cloudy urine with increased odour
 - Onset or increased episodes of incontinence
- Catheter related urethral trauma
- Difficulty with insertion
- Limited dexterity/hand function
- Limited transferring function
- Spasticity
- Other: _____

SpeediCath is pre-lubricated with a hydrophilic coating and polished eyelets which facilitate ease of insertion and improve patient comfort. Clinical evidence demonstrates a clear difference between single use hydrophilic catheters versus single use uncoated catheters. SpeediCath hydrophilic catheters were shown to reduce risk of urinary track infections in spinal cord injured patients ^{1,2}. Finally, several studies show reduced risk of urethral trauma by exerting less urethral friction and hence, causing less urethral micro-trauma, irritation and adherence during insertion and withdrawal, measured as withdrawal friction force and haematuria ^{3,4,5,6,7,8}.

The clinical data also suggests that compared to conventional uncoated catheters, using a SpeediCath catheter may minimize treatment costs, rehabilitation delays and may lower the risk of antibiotic resistance in this patient group.

We therefore request funding for this product (see prescription in the back) for ____ times a day catheterization for a total of _____ catheters per month.

Sincerely,


Doctor:



References available upon request:

1. Cardenas DD et al. Intermittent Catheterization With a Hydrophilic-Coated Catheter Delays Urinary Tract Infections in Acute Spinal Cord Injury: A Prospective, Randomized, Multicenter Trial. *PM&R* 2011;3:408-417.
2. De Ridder DJ et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomized parallel comparative trial. *Eur Urol* 2005;48:991-995.
3. Stensballe J et al. Hydrophilic-coated catheters for intermittent catheterization reduce complications of intermittent catheterization: their prevention and treatment urethral micro trauma: a prospective, randomized, participant-blinded, crossover study of three different types of catheters. *Eur Urol* 2005;48:978-983.
4. Wyndaele JJ. *Spinal Cord* 2002;40(10):536-541. Complications of intermittent catheterization: their prevention and treatment.
5. Biering-Sørensen F, Nielsen K, Hansen HV. *Spinal Cord* 1999b;37(4):299-300. Urethral epithelial cells on the surface on hydrophilic catheters after intermittent catheterization: cross-over study with two catheters.
6. Fader M, Moore KN, Cottenden AM, Pettersson L, Brooks R, Malone-Lee J. *BJU Int* 2001;88(4):373-377. Coated catheters for intermittent catheterization: Smooth or sticky?
7. Bagi P, Hannibalsen J, Permilid R, Stilling S, Looms D. *Urologia Internationalis*. (DOI:10.1159/000321900). Safety of a new compact male intermittent catheter: a randomised, cross-over, single blind study in healthy male volunteers.
8. Chartier-Kastler E, Lauge I, Ruffion A, Goossens D, Charvier K, Biering-Sørensen F. *Spinal Cord* 2011, in press. Safety of a new compact catheter for men with neurogenic bladder dysfunction: a randomised, cross-over, open-labelled study.

Doctor:



R_x Male

- SpeediCath Compact Set 12/18 FR (#28422)
- SpeediCath Compact 12/18 FR (#28692)
- SpeediCath
 - 10 FR (#27410)
 - 12 FR (#27412)
 - 14 FR (#27414)
 - 16 FR (#27416)
 - 18 FR (#27418)
- SpeediCath Coudé
 - 10 FR (#27490)
 - 12 FR (#27492)
 - 14 FR (#27494)
 - 16 FR (#27496)
- SpeediCath Paediatric
 - 6 FR (#27706)
 - 8 FR (#27708)
 - 10 FR (#27710)
- Other SpeediCath _____

R_x Female

- SpeediCath Compact Set
 - 10 FR (#28520)
 - 12 FR (#28522)
 - 14 FR (#28524)
- SpeediCath Compact Eve
 - 10 FR (#28110)
 - 12 FR (#28112)
 - 14 FR (#28114)
- SpeediCath
 - 8 FR (#27508)
 - 10 FR (#27510)
 - 12 FR (#27512)
 - 14 FR (#27514)
 - 16 FR (#27516)
- SpeediCath Paediatric
 - 6 FR (#27706)
 - 8 FR (#27708)
 - 10 FR (#27710)
- Other SpeediCath _____

Quantity 1 box ____ boxes Other _____

Repeats _____

Condition

- Quadriplegia Paraplegia Multiple sclerosis Spina Bifida
- Prostate cancer Benign prostatic hyperplasia Diabetes
- Bladder cancer Other _____

Additional information

Signature _____

Date ___/___/_____

The information in this document is intended for informational purposes only. The provider is ultimately responsible for all information communicated to the payer for reimbursement. As such, the provider should verify coverage criteria and other payer requirements. Coloplast Canada Corporation makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for any particular use and this information is not intended to provide direction or advice regarding any specific patients' situation. Coverage requirements will vary based on geographic location and reimbursement authority or entity.